Oxurion NV — Director's Dealing 2024

Mar 22, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – March 22, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on March 20, 2024, from Atlas Special Opportunities, LLC indicating that as of March 14, 2024, it held 269,785,563 shares of the then outstanding 5,753,951,723 shares, and therefore crossed below the threshold (5%) by virtue of the sale of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

________

Oxurion NV	Backstage Communication
Pascal Ghoson	Jurgen Vluijmans
Chief Executive Officer	Partner
Pascal.ghoson@oxurion.com	jurgen@backstagecom.be

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

cuSign Envelope ID: FDA7D6C8 A67C 4BC4 81A1-7E5CF87C8ECC

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
Identification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name		Address (for legal entities)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name		Address (for legal entities)
	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		14/03/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		5
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	5,753,951,723
10) Notified details	Please enter the denominator before filling in the data
A) Voting rights	Previous notification		After the transaction
Holders of voting rights	# of voting rights	# of voting rights Not linked to the Linked to securities securities	Linked to securities	% of voting rights Not linked to the

1.69% 4.69% - 4.69% - 1.00% 269,785,563 Start with "groups" of holders. Add subtotals with Z, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or le

TOTAL

DocuSign Envolope ID: FDA7D6C8 A67C 4BC4 81A1-7E5CF87C8ECC

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%
11	The totals will be updated once you have clicked on
	TOTAL (A & B)			# of voting rights	% of voting rights
			CALCULATE	269,785,563	4.69%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

			(DD/MM/YYYY
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

On 12 March 204, Alas Special Chel 36,217,39 than NY (= 0,25), benominator = 5,753,00 1.2 March 224 (un setment date on 14 Mach 2224), Alas Special
Opertunities LL odd 6,41,2

Done at New York
On	14/03/2024 (DD/MM/YYYY)
Name & capacity Patrick Vance, proxyholder	-DocuSigned by: Patrick Varie Signature -8A25E5A7A36F48C

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via the "

In addition, a signed copy in PDF format should also be
transmitted.